LT2806028T - Junginiai ir būdai, skirti polimorfobranduolinių ląstelių susitelkimo ir (arba) migracijos sumažinimui - Google Patents

Junginiai ir būdai, skirti polimorfobranduolinių ląstelių susitelkimo ir (arba) migracijos sumažinimui

Info

Publication number
LT2806028T
LT2806028T LTEP14154643.2T LT14154643T LT2806028T LT 2806028 T LT2806028 T LT 2806028T LT 14154643 T LT14154643 T LT 14154643T LT 2806028 T LT2806028 T LT 2806028T
Authority
LT
Lithuania
Prior art keywords
recruitment
migration
compounds
reducing
methods
Prior art date
Application number
LTEP14154643.2T
Other languages
English (en)
Lithuanian (lt)
Inventor
Charlotte Admyre
Lars-Gƶran AXELSSON
Oliver Von Stein
Arezou Zargari
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Publication of LT2806028T publication Critical patent/LT2806028T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
LTEP14154643.2T 2008-11-04 2009-10-28 Junginiai ir būdai, skirti polimorfobranduolinių ląstelių susitelkimo ir (arba) migracijos sumažinimui LT2806028T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11128408P 2008-11-04 2008-11-04
SE0802338 2008-11-04

Publications (1)

Publication Number Publication Date
LT2806028T true LT2806028T (lt) 2017-12-11

Family

ID=42153087

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14154643.2T LT2806028T (lt) 2008-11-04 2009-10-28 Junginiai ir būdai, skirti polimorfobranduolinių ląstelių susitelkimo ir (arba) migracijos sumažinimui

Country Status (11)

Country Link
US (2) US8877724B2 (enExample)
EP (2) EP2806028B1 (enExample)
JP (1) JP5749651B2 (enExample)
AU (1) AU2009311748B2 (enExample)
CA (1) CA2778938C (enExample)
DK (2) DK2806028T3 (enExample)
ES (2) ES2464731T3 (enExample)
HR (1) HRP20171360T1 (enExample)
LT (1) LT2806028T (enExample)
PL (1) PL2806028T3 (enExample)
WO (1) WO2010053430A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2560782T3 (es) * 2008-11-04 2016-02-22 Index Pharmaceuticals Ab Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC
EP2468866A1 (en) 2010-12-21 2012-06-27 Index Pharmaceuticals AB Biologically active oligonucleotides capable of modulating the immune system
CA2859698C (en) 2010-12-21 2021-03-02 Index Pharmaceuticals Ab Methods for identifying biologically active oligonucleotides capable of modulating the immune system
EP2468867A1 (en) 2010-12-21 2012-06-27 Index Pharmaceuticals AB Methods for identifying biologically active oligonucleotides capable of modulating the immune system
WO2012084991A1 (en) 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
US9873878B2 (en) * 2015-03-30 2018-01-23 University Of Louisville Research Foundation, Inc. Compositions and methods for use in treating silicosis and lung cancer
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
JP2021131228A (ja) * 2018-04-27 2021-09-09 国立大学法人 東京大学 難治性喘息の予防又は治療剤をスクリーニングする方法、及び難治性喘息の予防又は治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
SE9602300D0 (sv) * 1996-06-11 1996-06-11 Karolinska Innovations Ab New composition and methods
ES2246230T3 (es) 1999-03-18 2006-02-16 The Brigham And Women's Hospital, Inc. Compuestos de lipoxina y su utilizacion.
US6489311B1 (en) * 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
JP2006527741A (ja) * 2003-06-19 2006-12-07 シーティーティー キャンサー ターゲッティング テクノロジーズ オイ 細胞遊走の阻害剤
SE0400399D0 (sv) 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
WO2007030580A2 (en) * 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
WO2007030581A2 (en) 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
US8309529B2 (en) 2007-05-04 2012-11-13 Index Pharmaceuticals Ab Tumour growth inhibitory compounds and methods of their use
ES2560782T3 (es) 2008-11-04 2016-02-22 Index Pharmaceuticals Ab Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC
US20110280934A1 (en) 2008-11-04 2011-11-17 Asa Karlsson Increased Expression of Specific Antigens

Also Published As

Publication number Publication date
WO2010053430A1 (en) 2010-05-14
AU2009311748A1 (en) 2010-05-14
EP2342341A1 (en) 2011-07-13
AU2009311748B2 (en) 2014-08-21
EP2342341A4 (en) 2013-01-09
US10046006B2 (en) 2018-08-14
JP5749651B2 (ja) 2015-07-15
US20110301225A1 (en) 2011-12-08
US20150099799A1 (en) 2015-04-09
CA2778938C (en) 2019-07-02
EP2806028A2 (en) 2014-11-26
DK2342341T3 (da) 2014-05-12
US8877724B2 (en) 2014-11-04
EP2806028A3 (en) 2015-03-11
EP2342341B1 (en) 2014-03-05
HRP20171360T1 (hr) 2017-11-03
DK2806028T3 (en) 2017-10-09
ES2464731T3 (es) 2014-06-03
PL2806028T3 (pl) 2017-11-30
JP2012507307A (ja) 2012-03-29
EP2806028B1 (en) 2017-07-12
ES2641751T3 (es) 2017-11-13
CA2778938A1 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
HRP20171360T1 (hr) Spojevi i postupci smanjivanja novačenja i/ili seljenja polimorfonuklearnih stanica
IL267138A (en) Improved composition of cells and methods for its preparation
PL2205273T3 (pl) Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
EP2285217A4 (en) CONNECTIONS TO IMPROVE LEARNING AND MEMORY
ZA201006687B (en) Oxymethylene aryl compounds and uses thereof
TWI349334B (en) Dram structure and method of making the same
IL209740A0 (en) Methods for the production of ips cells using non-viral approach
EP2281696A4 (en) Decorative structure for article surface and processing method for it
IL208004A0 (en) Compounds and methods for reducing uric acid
EP2761016A4 (en) COMPOSITION OF REDOX REAGENTS FOR AN ELECTROCHEMICAL BIOSENSOR AND BIOSENSOR THEREWITH
EP2464652A4 (en) HAFNIUM AND ZIRCONIUM-CONTAINING PRECEDENTS AND METHOD OF USE THEREOF
EP2318508A4 (en) DETERMINATION OF RNA INTEGRITY
PL2646011T3 (pl) Sposoby redukcji napadowego objadania się lub kompulsywnego jedzenia
ZA201000381B (en) Use of yeast cell walls for treating and/or preventing hyper-insulinemia
IL211567A0 (en) Use of stem cells to prevent neuronal dieback
IL205452A0 (en) Methods of treating scleroderma
EP2121042A4 (en) COMPOUNDS AND METHOD FOR THE DETECTION OF CELLS
GB0817240D0 (en) Modified bacterial cell
PL2896614T3 (pl) Sposoby i związki do wytwarzania normorfinanów
GB0805670D0 (en) Increasing the plasticity of stem cells
TWM401709U (en) Screw structure and driver thereof
IL199671A0 (en) Compounds and methods for detection of cells
IL244553B (en) Altered placental cells
AU2009900131A0 (en) Cell migration
GB2452842B (en) Method of increasing activity